Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]Network OPaT. (accessed May 2015).

  • [2]Davidson J, Wilkinson A, Dantal J. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75, SS3-24 (2003)

  • [3]Wilkinson A, Davidson J, Dotta F. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin.Transplant 19:291-8. (2005)

  • [4]Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382-91 (2001)

  • [5]Hornum M, Clausen P, Idorn T, Hansen JM, Mathiesen ER, Feldt-Rasmussen B. Kidney transplantation improves arterial function measured by pulse wave analysis and endothelium-independent dilatation in uraemic patients despite deterioration of glucose metabolism. Nephrol Dial Transplant 26:2370-7 (2011)

  • [6]Koppe L, Pillon NJ, Vella RE. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 24:88-99 (2013)

  • [7]Meijers BK, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 26:759-61 (2011)

  • [8]Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 4:1932-8 (2009)

  • [9]Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 20:642-5 (2003).

  • [10]Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 21 (8): 2166-71 (2006)

  • [11]Gaston RS, Chandrakantan A. Diabetes mellitus after kidney transplantation. Am J Transplant 3:512-3 (2003)

  • [12]Pavkov ME, Knowler WC, Hanson RL, Nelson RG. Diabetic nephropathy in American Indians, with a special emphasis on the Pima Indians. Curr Diab Rep 8:486-93 (2008)

  • [13]Group TS. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 36:1735-41 (2013)

  • [14]Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 56, 1127-39 (2010)

  • [15]Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 8, 593-9 (2008).

  • [16]Taber DJ, Meadows HB, Pilch NA, Chavin KD, Baliga PK, Egede LE. Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation. Clinical transplant 27, 274-82 (2013).

  • [17]Bhalla V, Nast CC, Stollenwerk N, Tran S, Barba L, Kamil ES, Danovitch G, Adler SG. Recurrent and de novo diabetic nephropathy in renal allografts. Transplantation 15, 75 66-71 (2003)

  • [18]Kim H, Cheigh JS. Kidney transplantation in patients with type 1 diabetes mellitus: long-term prognosis for patients and grafts. Korean J Intern Med 16, 98-104 (2001)

  • [19]The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329, 977-86 (1993)

  • [20]Writing Team for the Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Research G. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290, 2159-67 (2003)

  • [21]Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-65 (1998)

  • [22]Lane JT, Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab 96, 3289-97 (2011)

  • [23]Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 36, 873-90; vii. (2007)

  • [24]Tatar E, Kircelli F, Demirci MS. Pre-transplant HbA1c level as an early marker for new-onset diabetes after renal transplantation. Int Urol Nephrol 45, 251-8 (2013)

  • [25]Salifu MO, Tedla F, Murty PV, Aytug S, McFarlane SI. Challenges in the diagnosis and management of new-onset diabetes after transplantation. Curr Diab rep 5, 194-9 (2005)

  • [26]Subramanian S, Trence DL. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 36, 891-905; vii (2007);

  • [27]Gosmanova EO, Tangpricha V, Gosmanov AR. Endocrine-metabolic pathophysiologic conditions and treatment approaches after kidney transplantation. Endocr Pract 18, 579-90 (2012)

  • [28]Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 27, 850-7 (2012)

  • [29]Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 91, 334-41 (2011)

  • [30]Spinelli GA, Felipe CR, Park SI, Mandia-Sampaio EL, Tedesco-Silva H, Jr., Medina-Pestana JO. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. Transplant Proc 43, 3730-7 (2011)

  • [31]Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 4, 175-86 (2011)

  • [32]Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3, 178-85 (2003)

  • [33]Miles AM, Sumrani N, Horowitz R. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 65, 380-4 (1998)

  • [34]Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62, 1440-6 (2002)

  • [35]Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 4, 1876-82 (2004)

  • [36]Valderhaug TG, Hjelmesaeth J, Hartmann A. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 54, 1341-9 (2011)

  • [37]Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354, 617-21 (1999)

  • [38]Zeymer U, Schwarzmaier-D’assie A, Petzinna D, Chiasson JL, Group S-NTR. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 11, 412-5 (2004)

  • [39]U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44, 1249-58 (1995)

  • [40]Baldwin D, Apel J. Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. Curr Diab Rep 13, 114-20 (2013)

  • [41]Investigators N-SS, Finfer S, Chittock DR. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360, 1283-97 (2009)

  • [42]Moghissi ES, Korytkowski MT, DiNardo M. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32, 1119-31 (2009)

  • [43]Hermayer KL, Egidi MF, Finch NJ. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab 97, 4399-406 (2012)

  • [44]Avanzini F, Marelli G, Donzelli W. Transition from intravenous to subcutaneous insulin: effectiveness and safety of a standardized protocol and predictors of outcome in patients with acute coronary syndrome. Diabetes Care 3, 1445-50 (2011)

  • [45]Schmeltz LR, DeSantis AJ, Schmidt K. Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract 12, 641-50 (2006)

  • [46]Choi SH, Kim TH, Lim S, Park KS, Jang HC, Cho NH. Hemoglobin A1c as a diagnostic tool for diabetes screening and new-onset diabetes prediction: a 6-year community-based prospective study. Diabetes Care 34, 944-9 (2011)

  • [47]Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG. Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 13, 514-9 (1996)

  • [48]Werzowa J, Hecking M, Haidinger M. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 95, 456-62 (2013)

  • [49]Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 4, 2135-3848 (2004)

  • [50]Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 92, e56-7 (2011)

  • [51]Graefe-Mody U, Friedrich C, Port A. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab 13, 939-46 (2011)

  • [52]Sadhu A, Schwartz SS, Herman ME. The rationale for use of incretins in the management of new onset diabetes after transplantation (NODAT). Endocr Prac 21, 814-22 (2015)

  • [53]Krisl J, Gaber AO, Sadhu AR. Long acting glucagon like peptide-1 (GLP-1) agonist therapy in post solid organ transplant patients. Am J Transplant 15, 523 (2014)

  • [54]Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care 36, e171-2 (2013)

  • [55]Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 41, 480-7 (2003)

  • [56]Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 30, 777-88 (1998)

  • [57]Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 116, 1793-801 (2006)

  • [58]Modlin CS, Flechner SM, Goormastic M. Should obese patients lose weight before receiving a kidney transplant? Transplantation 64, 599-604 (1997)

  • [59]Gill IS, Hodge EE, Novick AC, Steinmuller DR, Garred D. Impact of obesity on renal transplantation. Transplant Proc 25, 1047-8 (1993)

  • [60]Gore JL, Pham PT, Danovitch GM. Obesity and outcome following renal transplantation. Am J Transplant 6, 357-63. (2006)

  • [61]Halme L, Eklund B, Kyllonen L, Salmela K. Is obesity still a risk factor in renal transplantation? Transpl Int 10, 284-8 (1997)

  • [62]Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 73, 70-4 (2002)

  • [63]Cacciola RA, Pujar K, Ilham MA, Puliatti C, Asderakis A, Chavez R. Effect of degree of obesity on renal transplant outcome. Transplant Proc 40, 3408-12 (2008)

  • [64]Kawano T, Saito T, Yasu T. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism 54, 653-6 (2005)

  • [65]Jagannathan-Bogdan M, McDonnell ME, Shin H. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 186, 1162-72 (2011)

  • [66]Heinbokel T, Floerchinger B, Schmiderer A. Obesity and its impact on transplantation and alloimmunity. Transplantation 96, 10-6 (2013)

  • [67]Humar A, Ramcharan T, Denny R, Gillingham KJ, Payne WD, Matas AJ. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 72, 1920-3 (2001)

  • [68]Singh D, Lawen J, Alkhudair W. Does pretransplant obesity affect the outcome in kidney transplant recipients? Transplant Proc 37, 717-20 (2005)

  • [69]Glanton CW, Kao TC, Cruess D, Agodoa LY, Abbott KC. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Intl 63, 647-53 (2003)

  • [70]Weiss ES, Allen JG, Russell SD, Shah AS, Conte JV. Impact of recipient body mass index on organ allocation and mortality in orthotopic heart transplantation. J Heart Lung Transplant 28, 1150-7 (2009)

  • [71]MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis 55, 69-76 (2010)

  • [72]Buchwald H, Avidor Y, Braunwald E. Bariatric surgery: a systematic review and meta-analysis. JAMA 292, 1724-37 (2004)

  • [73]Modanlou KA, Muthyala U, Xiao H. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation 87, 1167-73 (2009)

  • [74]Takata MC, Campos GM, Ciovica R. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg Obes relat Dis 4, 159-64 discussion 64-5 (2008)

  • [75]Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant 22, 281-91 (2008)

  • [76]Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant 10, 414-9 (1996)

  • [77]Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-607 (1988)

  • [78]Alberti KG, Eckel RH, Grundy SM. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-5 (2009)

  • [79]Sharif A, Baboolal K. Metabolic syndrome and solid-organ transplantation. Am J Transplant 10, 12-7 (2010)

  • [80]Gami AS, Witt BJ, Howard DE. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49, 403-14 (2007)

  • [81]de Vries AP, Bakker SJ, van Son WJ. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 4, 1675-83 (2004)

  • [82]Porrini E, Delgado P, Bigo C. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 48, 134-42 (2006)

  • [83]Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066-72 (2005)

  • [84]Ho JS, Cannaday JJ, Barlow CE, Mitchell TL, Cooper KH, FitzGerald SJ. Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol 102, 689-92 (2008)

  • [85]Courivaud C, Kazory A, Simula-Faivre D, Chalopin JM, Ducloux D. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 83, 1577-81 (2007)

  • [86]Hjelmesaeth J, Flyvbjerg A, Jenssen T. Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy. Clin J Am Soc Nephrol 1, 575-82 (2006)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

Glucometabolic disease in the kidney transplant patient

Archana R. Sadhu 1, Devin Steenkamp 2, Marie E. McDonnell 3,*
Affiliations
Article Info

1 Weill Cornell Medical College at Houston Methodist Hospital, Houston, Texas

2 Boston University School of Medicine, Department of Medicine, Section of Endocrinology, Boston, Massachusetts

3 Harvard Medical School, Brigham and Women’s Hospital, Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Boston, Massachusetts

*Author to whom correspondence should be addressed.

 

Abstract

The comprehensive care of the kidney transplant (KT). patient includes a broad clinical assessment to detect and stage metabolic disease both before and after transplantation. In this review, the metabolic consequences of KT in both the short and long term will be explored in the context of new data and a synthesis proposed based upon what has been studied for over two decades. A review of the changes in epidemiology introduces a discussion of the current state of the literature for the diagnosis and management of diabetes after KT, obesity and the metabolic syndrome.

Keywords

  • Review
  • NODAT
  • Diabetes
  • Metabolic syndrome
  • Obesity
  • Review

References